Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Galmed Pharma(GLMD) the EBIT is -2.775 M (-31.58%);the EPS is -2.86 (+43.43%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.00B31.58%
----
----
EPS
-2.859843.43%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf